Comparative Pharmacology
Head-to-head clinical analysis: ORPHENGESIC versus ORPHENGESIC FORTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORPHENGESIC versus ORPHENGESIC FORTE.
ORPHENGESIC vs ORPHENGESIC FORTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ORPHENGESIC (oxycodone/naloxone) is a combination of an opioid agonist (oxycodone) and an opioid antagonist (naloxone). Oxycodone acts primarily on mu-opioid receptors in the CNS to produce analgesia; naloxone, at oral doses, has low systemic bioavailability but antagonizes opioid effects on gut opioid receptors to reduce constipation.
Opioid agonist; primarily mu-opioid receptor agonism, with additional kappa and delta receptor activity, leading to altered pain perception and analgesic response.
10 mg oral every 4-6 hours as needed; maximum 60 mg per day.
1-2 tablets (325-650 mg acetaminophen/30-60 mg codeine) orally every 4-6 hours as needed; maximum 8 tablets per day.
None Documented
None Documented
3-4 hours in adults; prolonged in hepatic impairment (up to 6-8 hours) and elderly (up to 5 hours). Requires dose adjustment in cirrhosis.
2-4 hours; prolonged to 10-20 hours in hepatic impairment.
Renal: 70-80% as conjugates; fecal: 10-20% via biliary elimination; <5% unchanged drug in urine.
Renal: 87% (55% unchanged, 32% as glucuronide conjugate); Biliary/Fecal: <5% as metabolites.
Category C
Category C
Muscle relaxant combination
Muscle relaxant combination